Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma

Frontiers in Bioscience

Volumn 12, Issue 9, 2007, Pages 3566-3575

  Wang, Siqing ^a   Hong, Sungyoul ^a   Wezeman, Michele ^a   Qian, Jianfei ^a   Yang, Jing ^a   Yi, Qing ^a,b  

^a University of Texas ^*  (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Dendritic cells; Idiotype; Immune system; Immunotherapy; Mouse model; Multiple myeloma

Indexed keywords

MURINAE; MUS;

CANCER VACCINE;

ANIMAL; ARTICLE; C57BL MOUSE; CELLULAR IMMUNITY; DENDRITIC CELL; FLOW CYTOMETRY; IMMUNOLOGY; MALE; MOUSE; MULTIPLE MYELOMA;

ANIMALS; CANCER VACCINES; DENDRITIC CELLS; FLOW CYTOMETRY; IMMUNITY, CELLULAR; MALE; MICE; MICE, INBRED C57BL; MULTIPLE MYELOMA;

EID: 34347207934     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2335     Document Type: Article

References (34)

1. Barlogie, B., J. Shaughnessy, G. Tricot, J. Jacobson, M. Zangari, E. Anaissie, R. Walker, and J. Crowley. Treatment of multiple myeloma. Blood 103, 20-32 (2004) (Pubitemid 38029914)
2. Kyle, R. A. and SV. Rajkumar. Multiple myeloma. N Engl J Med 351, 1860-73 (2004)
3. Yi, Q. Immunotherapy in multiple myeloma: current strategies and future prospects. Expert Rev Vaccines 2, 391-8 (2003) (Pubitemid 36713365)
4. Anderson, K. C. The role of immunomodulatory drugs in multiple myeloma. Semin Hematol 40, 23-32 (2003) (Pubitemid 37532257)
5. Neelapu, SS., LW. Kwak, CB, Kobrin, CW. Reynolds, JE. Janik, K. Dunleavy, T. White, L. Harvey, R. Pennington, M. Stetler-Stevenson, ES, Jaffe, and SM. Steinberg. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med 11, 986-91 (2005) (Pubitemid 41294445)
6. Bendandi, M., CD. Gocke, CB. Kobrin, FA. Benko, LA. Sternas, R. Pennington, TM. Watson, CW. Reynolds, BL. Gause, PL. Duffey, ES. Jaffe, SP. Creekmore, SP. Creekmore, DL. Longo, and L. W. Kwak. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 5, 1171-7 (1999) (Pubitemid 29474422)
7. Massaia, M., P. Borrione, S. Battaglio, S. Mariani, E. Beggiato, P. Napoli, C. Voena, A. Bianchi, M. Coscia, B. Besostri, S. Peola, T. Stiefel. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 94, 673-83 (1999) (Pubitemid 29323881)
8. Yi, Q., R. Desikan, B. Barlogie, and N. Munshi. Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br J Haematol 117, 297-305 (2002) (Pubitemid 34451144)
9. Reichardt, V. L., CY. Okada, A. Liso, CJ. Benike, KE. Stockerl-Goldstein, EG. Engleman, KG. Blume, and R. Levy. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study. Blood 93, 2411-9 (1999) (Pubitemid 29153646)
10. Timmerman, J. M., DK. Czerwinski, TA. Davis, FJ. Hsu, C. Benike, ZM. Hao, B. Taidi, R. Rajapaksa, CB. Caspar, CY. Okada, A. van Beckhoven, and TM. Liles. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99, 1517-26 (2002) (Pubitemid 34533020)
11. Hsu, F. J., C. Benike, F. Fagnoni, TM. Liles, D. Czerwinski, B. Taidi, EG. Engleman, and R. Levy. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2, 52-8 (1996) (Pubitemid 26028073)
12. Radl, J., ED. De Glopper, HR. Schuit, and C. Zurcher. Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J Immunol 122, 609-13 (1979) (Pubitemid 9089221)
13. Asosingh, K., J. Radl, I. Van Riet, B. Van Camp, and K. Vanderkerken. The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol J 1, 351-6 (2000)
14. Garrett, I. R., S. Dallas, J. Radl, and GR. Mundy. A murine model of human myeloma bone disease. Bone 20, 515-20 (1997) (Pubitemid 27270464)
15. Mundy, G. Preclinical models of bone metastases. Semin Oncol 28, 2-8 (2001) (Pubitemid 32844922)
16. Wen, Y. J., B. Barlogie, and Q. Yi. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood 97, 1750-5 (2001) (Pubitemid 32217243)
17. Kwak, L. W., HA. Young, RW. Pennington, and SD. Weeks. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci U S A 93, 10972-7 (1996) (Pubitemid 26333102)
18. Lutz, M. B., N. Kukutsch, AL. Ogilvie, S. Rossner, F. Koch, N. Romani, G. Schuler. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223, 77-92 (1999) (Pubitemid 29096240)
19. Mori, Y., N. Shimizu, M. Dallas, M. Niewolna, B. Story, PJ. Williams, GR. Mundy, T. Yoneda. Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 104, 2149-54 (2004) (Pubitemid 39297870)
20. Wen, Y. J., R. Min, G. Tricot, B. Barlogie, and Q. Yi. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood 99, 3280-5 (2002) (Pubitemid 34525308)
21. Liso, A., KE. Stockerl-Goldstein, S. Auffermann-Gretzinger, CJ. Benike, V. Reichardt, A. van Beckhoven, R. Rajapaksa, EG. Engleman, KG. Blume, and Levy R. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 6, 621-7 (2000)
22. Cohen, S., J. Haimovich, and N. Hollander. B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice. J Immunother 28, 461-6 (2005) (Pubitemid 41232567)
23. Zitvogel, L., JI. Mayordomo, T. Tjandrawan, AB. DeLeo, MR. Clarke, MT. Lotze, and WJ. Storkus. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183, 87-97 (1996) (Pubitemid 26028748)
24. Osterborg, A., Q. Yi, L. Henriksson, J. Fagerberg, S. Bergenbrant, M. Jeddi-Tehrani, U. Ruden, AK. Lefvert, G. Holm, and H. Mellstedt. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8-and CD4-specific T-cell responses. Blood 91, 2459-66 (1998) (Pubitemid 28155521)
25. Nishimura, T., K. Iwakabe, M. Sekimoto, Y. Ohmi, T. Yahata, M. Nakui, T. Sato, S. Habu, H. Tashiro, M. Sato, and A. Ohta. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 190, 617-27 (1999) (Pubitemid 29428646)
26. Basak, S. K., A. Harui, M. Stolina, S. Sharma, K. Mitani, SM. Dubinett, and MD. Roth. Increased dendritic cell number and function following continuous in vivo infusion of granulocyte macrophage-colony-stimulating factor and interleukin-4. Blood 99, 2869-79 (2002) (Pubitemid 34525376)
27. Sallusto, F. and A. Lanzavecchia. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179, 1109-18 (1994)
28. Eguchi, J., K. Hiroishi, S. Ishii, T. Baba, T. Matsumura, A. Hiraide, H. Okada, and M. Imawari. Interleukin-4 gene transduced tumor cells promote a potent tumor-specific Th1-type response in cooperation with interferon-alpha transduction. Gene Ther 12, 733-41 (2005) (Pubitemid 40668412)
29. Schuler, T., T. Kammertoens, S. Preiss, P. Debs, N. Noben-Trauth, and T. Blankenstein. Generation of tumorassociated cytotoxic T lymphocytes requires interleukin 4 from CD8 (+) T cells. J Exp Med 194, 1767-75 (2001) (Pubitemid 34028656)
30. Kwak, L. W., MJ. Campbell, AD. Zelenetz, and R. Levy. Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin. Blood 76, 2411-7 (1990)
31. Kwak, L. W., MJ. Campbell, DK. Czerwinski, S. Hart, RA. Miller, and R. Levy. Induction of immune responses in patients with B-cell lymphoma against the surfaceimmunoglobulin idiotype expressed by their tumors. N Engl J Med 327, 1209-15 (1992)
32. Hsu, F. J., CB. Caspar, D. Czerwinski, LW. Kwak, TM. Liles, A. Syrengelas, B. Taidi-Laskowski, and R. Levy. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood 89, 3129-35 (1997)
33. Croese, J. W., MH. Van den Enden-Vieveen, and J. Radl. Immune regulation of 5T2 mouse multiple myeloma. II. Immunological treatment of 5T2 MM residual disease. Neoplasma 38, 467-74 (1991)
34. Thielemans, K., DG. Maloney, T. Meeker, J. Fujimoto, C. Doss, RA. Warnke, J. Bindl, J. Gralow, RA. Miller, and R. Levy. Strategies for production of monoclonal antiidiotype antibodies against human B cell lymphomas. J Immunol 133, 495-501 (1984) (Pubitemid 14082080)